Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study
Spesolimab 600 mg SC LD followed by 300 mg SC q4w provides sustained improvement of skin symptoms and QoL burden in a substantially higher proportion of patients with GPP versus placebo.
Authors
- Ming Tang (ORCID: https://orcid.org/0000-0002-6451-8648)
- Matthias Augustin (ORCID: https://orcid.org/0000-0002-4026-8728)
- Kenneth B. Gordon (ORCID: https://orcid.org/0000-0002-9347-0292)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Juliet N. Barker (ORCID: https://orcid.org/0000-0002-9030-183X)
- Christian Thoma (ORCID: https://orcid.org/0000-0002-5702-2492)
- Patrick Hofmann (ORCID: https://orcid.org/0000-0003-2773-3696)
- Yayoi Tada
- Alice B. Gottlieb
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Universität Hamburg (DE)
- King's College London (GB)
- Medical College of Wisconsin (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Boehringer Ingelheim (China) (CN)
- Teikyo University (JP)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1016/j.jaad.2025.01.089
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- Boehringer Ingelheim